September 12, 2012 08:30 AM Eastern Time
Plasma Surgical Adds Trio of Experienced Leaders to the Management Team
Company focuses on commercialization stage of the business and fueling growth of its PlasmaJet® system.
ROSWELL, Ga.-- Plasma Surgical, creator of PlasmaJet®, an advanced energy device designed for efficient cutting, coagulation and ablation of tissue, has bolstered an already- seasoned management team by introducing new leaders with diverse industry healthcare backgrounds, as the company shifts its focus to commercial growth.
“The company and its scientific inventors have developed world-class technology that can truly advance clinical care,” said Richard J. Morello, Plasma Surgical’s newly appointed president and chief executive officer. “I have spent the last 20 years in different areas of the healthcare industry, and am pleased to have the opportunity to help transform Plasma Surgical’s unmatched innovation into commercial success.”
Mr. Morello joins the company after serving as senior vice president of Proventys, Inc., a healthcare technology start-up that pioneered the creation of web-based decision support tools in oncology. Prior to Proventys, Mr. Morello led the Strategic Initiatives division of Joslin Diabetes Center, a Harvard Medical Affiliate and world-leading institution based in Boston. There, he forged innovative partnerships with industry and spun out a telemedicine business focused on delivering more efficient care of diabetic retinopathy. Prior to Joslin, he served as a partner in the Health & Life Sciences practice of Mercer Management Consulting where he led several engagements with pharmaceutical companies, health insurers, and other clients.
“Plasma Surgical has built strong assets – from an extensive patent portfolio to scalable manufacturing and quality system capabilities - as it developed its core PlasmaJet technology and prepared for growth,” added Mr. Morello. “With the addition of other talented industry leaders, we are poised to achieve our mission of advancing surgical and therapeutic care for patients.”
Filling Out the Leadership Team
With experienced leaders in place representing science, R&D, manufacturing, strategic marketing and other areas, Plasma Surgical recently added two industry veterans to fill key sales and marketing and regulatory affairs roles.
Colin Preis joined the company as vice president, sales and marketing for North America after nearly 16 years at Covidien, most recently serving as the general manager for its $250 million SharpSafety division. In his new role at Plasma Surgical, Mr. Preis will drive commercialization plans for the U.S. and other markets and help devise ongoing business development strategies.
The company also added Angela Brown as vice president, quality assurance and regulatory affairs. Ms. Brown has nearly 20 years of experience in quality and regulatory roles in the medical device industry, including 14 years at Teleflex and most recently serving as the director of regulatory affairs at C.R. Bard. She will now oversee an established global function team and lead the organization through its commercialization stage.
“Both Colin and Angela bring experience and skills that are critical for our success,” said Mr. Morello. “Not only have they played leadership roles at well-established device companies, but they possess the energy and rigor that are crucial in early-stage, high-growth companies.”
About Plasma Surgical
Plasma Surgical is harnessing plasma technology to make a true difference in the way surgical and therapeutic care is delivered to patients. The company’s flagship device, the PlasmaJet® system, is an advanced energy device for open and laparoscopic surgical procedures. Designed for efficient cutting, coagulation and ablation of tissue without the transfer of an electrical current through the patient, PlasmaJet offers surgeons an effective solution to reduce thermal spread and preserve vital tissue. Founded on world-class research in plasma physics in 1999, the company is headquartered in Atlanta and has offices in the United Kingdom and France. For more information, please visit www.plasmasurgical.com.
For more information visit plasmasurgical.com